Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical DLX105 in mild-to-moderate psoriasis vulgaris
2013-001885-41Phase 2Completed
- Sponsor
- Delenex Therapeutics
- Start
- May 2013
- Modality
- scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in plaque psoriasis comparing Topical DLX105 with Topical placebo (2 arms). Primary endpoint: Safety and tolerability of topical DLX105. Started May 2013; status: completed.
02
Drugs
DLX105
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2013-001885-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001885-41.